Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Plexxikon has signed a broad kinase screening agreement with Invitrogen Corporation to profile kinase inhibitor libraries in order to boost drug discovery efforts.
Subscribe to our email newsletter
Under the agreement, Plexxikon’s libraries will be screened in parallel against the most therapeutically relevant kinase targets among a panel of 100 enzymes available currently. Plexxikon anticipates a significant expansion of its preclinical portfolio of novel drug candidates for oncology, inflammation and metabolic disorders this year as a result of this further acceleration in its drug discovery process.
Plexxikon already is developing a number of kinase inhibitors from these libraries, including PLX647, a dual Kit and Fms kinase inhibitor for the treatment of rheumatoid arthritis and other inflammatory diseases, and a B-Raf inhibitor for the treatment of cancer.
“Invitrogen’s use of functional activity assays will provide us with the optimal read-out for determining selectivity and identification of the best drug candidates,” said Gideon Bollag, vice president of discovery biology at Plexxikon. “Based on previous validation work, we anticipate producing optimized development candidates in less than six months, thereby further accelerating our timeline to investigational new drug (IND) filing.”